Antiresorptive drugs, such as the bisphosphonates and the RANKL inhibitor denosumab,
are currently the most widely used osteoporosis medications. These drugs increase bone …

The goal of osteoporosis management is to prevent fractures. Several pharmacological
agents are available to lower fracture risk, either by reducing bone resorption or by …

Bone forming approaches to treat patients with severe osteoporosis are effective, but
treatment options are limited and there is an unmet clinical need for additional drugs. This …

It is now well recognized that over the lifetime of a patient with osteoporosis, more than one
medication will be needed to treat the disease and to decrease fracture risk. Though current …

Osteoporosis is a major public health problem that is characterized by microarchitectural
deterioration, low bone mass, and increased risk of fractures. Currently, many women and …

As osteoporosis therapy options have expanded, and clinical guidelines have begun to
embrace the concept of limited treatment courses and “drug holidays,” the choices that …

Romosozumab (ROMO) is a recently approved monoclonal antibody (approved by the US
Food and Drug Administration [FDA] in April 2019 and Health Canada in June 2019) for the …

Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the
canonical Wnt signaling bone formation pathway. Romosozumab is a humanized …

Future therapeutic targets in osteoporosis : Current Opinion in Rheumatology Future therapeutic
targets in osteoporosis : Current Opinion in Rheumatology Log in or Register Subscribe to …

Osteoporosis is a systemic skeletal disease characterized by low bone mass and
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility …